A Phase 1 Study of LY2940680 in Japanese Patients with Advanced Solid Tumors
- Conditions
- eoplasm Metastasis
- Registration Number
- JPRN-jRCT2080222179
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic. The participants must be an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease
- Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors Guideline Version 1.1
- Have adequate organ function
- Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy for at least 3 weeks prior to study enrollment, and have recovered from the acute effects of any such therapy
- Males must agree to use medically approved barrier contraceptive precautions during the study and for 6 months following the last dose of study drug
- Females with child bearing potential must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug; have had a negative serum pregnancy test equal to or less than 7 days before the first dose of study drug
- Have an estimated life expectancy which will permit the participant to complete 2 cycles of treatment
- Are able to swallow tablets
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method